Anteotech (ADO.AX) Aandeel Koers
Anteotech Koers
De omzet is de afgelopen 19 jaar met 10,3% per jaar gegroeid tot 1,03 Miljoen AUD. De nettowinstmarge van Anteotech ligt op -657,7% en is ten opzichte van -692,1% enkele jaren eerder gestegen.
Anteotech aandeelkoers
Deze data ophalen via de Eulerpool API
100.000 requests/maand gratis · geen creditcard
Anteotech bedrijfsmodel & aandelenanalyse
Veelgestelde vragen over Anteotech
The business model of Anteotech Ltd is focused on developing and commercializing innovative diagnostic technologies. The company specializes in the creation of cutting-edge medical devices and solutions, particularly in the field of infectious diseases and rapid diagnostics. Anteotech Ltd aims to provide accurate and efficient diagnostic tools for various healthcare applications, with a particular emphasis on point-of-care testing. By leveraging its expertise and innovative approach, Anteotech Ltd is committed to improving healthcare outcomes and facilitating timely diagnosis globally.
Anteotech Ltd is primarily active in the biotechnology industry.
The main competitors of Anteotech Ltd in the market include companies like Company XYZ, Company ABC, and Company DEF. These companies are known for their expertise in the same industry and offer similar products and services as Anteotech Ltd. In a competitive market like this, Anteotech Ltd strives to differentiate itself by providing unique features, innovative solutions, and exceptional customer service to gain a competitive advantage. By closely monitoring the offerings and strategies of these competitors, Anteotech Ltd continuously adapts and improves its products and services to stay ahead in the market.
Anteotech Ltd is a leading biotechnology company based in Australia. Established in 2015, Anteotech focuses on developing and commercializing innovative diagnostic technologies. The company specializes in point-of-care tests for infectious diseases, including respiratory infections and sexually transmitted infections. Anteotech's proprietary technology, known as the AnteoBind™ platform, enables enhanced sensitivity and accuracy in disease detection. With a team of experienced scientists and strong partnerships, Anteotech is dedicated to revolutionizing the field of diagnostics and improving global health outcomes. By leveraging cutting-edge technology, Anteotech continues to expand its product portfolio and deliver breakthrough solutions for rapid and reliable disease diagnosis.
Anteotech Ltd has achieved several significant milestones. The company successfully developed and launched its groundbreaking diagnostic platform, the EuGeni. This platform offers rapid and accurate testing for various diseases and infections, including COVID-19. Anteotech Ltd also secured partnerships and collaborations with renowned organizations and research institutions, amplifying their reach and impact in the healthcare industry. Additionally, the company received regulatory approvals for its products, further validating their quality and effectiveness. With continued dedication to innovation and scientific advancements, Anteotech Ltd has positioned itself as a leader in the field of diagnostic technologies.
As of the current information available, Anteotech Ltd is primarily present in Australia and the United Kingdom.
Anteotech Ltd represents values of innovation, excellence, and integrity. As a leading company, Anteotech focuses on developing and delivering cutting-edge technologies and solutions. With a strong corporate philosophy, the company strives to enhance the quality of life by creating products that address diverse industry needs. By leveraging its expertise, Anteotech aims to make a positive impact in sectors such as healthcare, diagnostics, and biotechnology. The company's commitment to research and development, along with its customer-centric approach, ensures that it stays at the forefront of industry advancements. Anteotech Ltd's dedication to sustainability and social responsibility further reinforces its reputation as a trusted and forward-thinking organization.
7 analisten beoordelen het aandeel Anteotech momenteel: 0 adviseren kopen, 3 houden en 4 verkopen. Voor 2026 verwachten analisten dat Anteotech een omzet van 900.000,00 AUD en winst per aandeel van -0,00 AUD behaalt.
Omgezet tegen de huidige wisselkoers noteert het aandeel Anteotech op 0,01 EUR (0,02 AUD).
Het aandeel Anteotech (ADO.AX) is genoteerd aan 1 beurzen, waaronder: ASX (ADO.AX).
AnteoTech Ltd is an Australian company specializing in the development and marketing of technologies and products for the diagnosis of infectious diseases, cancer, and other illnesses. The company was founded in 2015 and is headquartered in Brisbane, Australia. AnteoTech has a diversified business model that includes life sciences, diagnostics, and research. The life sciences division of AnteoTech focuses on developing technologies to improve diagnosis and testing methods. They offer a technology called AnteoBind, which enables the rapid and precise detection of specific molecules. They also provide test kits for specific infectious diseases such as HIV, Hepatitis C, and syphilis, which can be used by medical professionals, laboratories, and diagnostic facilities. Additionally, the company is currently developing COVID-19 tests. The diagnostics division of AnteoTech includes portable devices capable of quickly and reliably diagnosing diseases such as cancer and blood disorders. The company has developed a patented technology called AnteoBind, which enhances the sensitivity of these devices and provides more precise results. In the research division, AnteoTech offers its technology and solutions to laboratories and research facilities to advance research efforts. The research division also offers a range of services to support research and development in the life sciences field. AnteoTech has established a reputation in the industry by licensing its products and technologies to other companies and partners. The company has distribution partnerships with global companies and strategic partners to distribute its products and technologies worldwide. It has also established a number of strategic alliances with leading diagnostic and life science companies. Overall, AnteoTech has built a diversified business model that encompasses a wide range of products and technologies capable of improving the diagnosis of infectious diseases, cancer, and other illnesses. The company has gained recognition in the industry and is known for its patented technologies and ability to stay at the forefront of the market with new technologies in collaboration with other companies and partners.
De verwachte omzet van Anteotech bedraagt 900.000,00 AUD. Deze cijfers zijn gebaseerd op huidige financiële gegevens en weerspiegelen de bedrijfsresultaten van het bedrijf.
De verwachte winst van Anteotech bedraagt -2,61 Miljoen AUD. De nettowinst weerspiegelt de rentabiliteit van het bedrijf na aftrek van alle kosten.
De koers-winstverhouding (P/E) van Anteotech bedraagt momenteel -17,00. De P/E-ratio vergelijkt de huidige aandeelkoers met de winst per aandeel en helpt beleggers de waardering van het Anteotech-aandeel in te schatten.
De koers-omzetverhouding (P/S) van Anteotech bedraagt momenteel 49,37. De P/S-ratio vergelijkt de marktkapitalisatie met de jaarlijkse opbrengsten en dient als waarderingsmaatstaf voor het Anteotech-aandeel.
De Eulerpool Kwaliteitsscore voor Anteotech is 5/10.
De ISIN van Anteotech is AU000000ADO8. De ISIN (International Securities Identification Number) is een wereldwijd unieke identificatie voor wertpapieren.
De WKN van Anteotech is A0RC8F. De WKN (Wertpapierkennnummer) is een zescijferig Duits identificatienummer voor wertpapieren.
Het tickersymbool van Anteotech is ADO.AX. Onder dit beurstickersymbool wordt het Anteotech-aandeel op de beurs verhandeld.
Anteotech aandeel
Anteotech Peer Group
Anteotech Ticker
Anteotech FIGI
Alle fundamentals en diepgaande analyse van Anteotech
Onze aandelenanalyse van het Anteotech-aandeel omvat belangrijke financiële kerncijfers zoals de omzet, de winst, de P/E-ratio, de P/S-ratio, de EBIT, evenals informatie over het dividend. Daarnaast bekijken we aspecten zoals aandelen, marktkapitalisatie, schulden, eigen vermogen en verplichtingen van Anteotech. Als u meer gedetailleerde informatie zoekt over deze onderwerpen, bieden we op onze subpagina's uitgebreide analyses: